Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2) Meeting Abstract

  

Authors:	Azuma, M.; Yang, D.; Carpanu, M.; Hollywood, E.; Lue-Yat, M.; Zhang, W.; Danenberg, K. D.; Danenberg, P. V.; Saltz, L.; Lenz, H.
Abstract Title:	Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)
Meeting Title:	43rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	25
Issue:	18 Suppl.
Meeting Dates:	2007 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2007-06-20
Start Page:	191s
Language:	English
ACCESSION:	WOS:000455043700767
PROVIDER:	wos
DOI:	10.1200/jco.2007.25.18_suppl.4113
Notes:	Meeting Abstract: 4113 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/141577